{"id":926765,"date":"2026-01-13T08:58:18","date_gmt":"2026-01-13T13:58:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/"},"modified":"2026-01-13T08:58:18","modified_gmt":"2026-01-13T13:58:18","slug":"aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/","title":{"rendered":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer"},"content":{"rendered":"<h2>\nSeasoned leader with global commercialization and marketing expertise<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Jan.  13, 2026  (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (\u201cAligos\u201d, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company\u2019s global commercial capabilities and serve as a member of Aligos\u2019 Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas.<\/p>\n<p>\u201cAs we continue to progress the Phase 2 B-SUPREME study of pevifoscorvir sodium, we have begun planning for the future and how best to bring this therapy to patients. I am excited to welcome Jim to Aligos as our Chief Commercial Officer who will spearhead our commercial readiness efforts,\u201d said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. \u201cThis is an important role for Aligos as we approach late-stage development. Bringing Jim on is another step closer to our vision of delivering better outcomes for patients in need.\u201d<\/p>\n<p>\u201cI am thrilled to join Aligos as the company progresses towards late-stage development,\u201d stated Jim Hassard, MBA, Chief Commercial Officer at Aligos. \u201cThis is an exciting time for the chronic hepatitis B virus infection field, as next-generation therapies are closer to helping patients in need of better options. I look forward to building the necessary global commercial infrastructure to position pevifoscorvir sodium for future success.\u201d<\/p>\n<p>Prior to joining Aligos, Jim was Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals where he built the commercial capabilities and launch strategies for more than four rare disease programs. Earlier in his career, Mr. Hassard held positions of increasing responsibility at Coherus Oncology, Amgen, and Merck, launching multiple pharmaceutical products in therapeutic areas including hepatitis, oncology, and nephrology. He has global experience in the United States, Canada and Europe, including as general manager of Amgen Portugal. Mr. Hassard earned a Bachelor of Science in Pharmacology from the University of Toronto, followed by a Master\u2019s in Business Administration from Nova Southeastern University.<\/p>\n<p>\n        <strong>About Aligos<\/strong>\n      <\/p>\n<p>Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&amp;D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u-Vuz2xHefWkFGbI9ERgNmXyudoGfc_8KvVttWkKaFFXPUkgpzunBY3dWD1f291ookvpIeSV4Wk3UtIsYe-6xw==\" rel=\"nofollow\" target=\"_blank\">www.aligos.com<\/a> or follow us on LinkedIn or X.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered \u201cforward-looking statements,\u201d including without limitation, statements regarding Aligos\u2019 research, development and commercial activities, including the potential success of clinical trials, regulatory approval and product launches. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos\u2019 clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos\u2019 capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos\u2019 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. <br \/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><strong>Aligos Therapeutics<\/strong><\/p>\n<p>\n        <strong>Contact <\/strong><br \/>\n        <br \/>Jordyn Tarazi<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>+1 (650) 910-0427<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h4nBTfTa71_Ue3u8a0anRLOYmzWTh6GkHSEVFO_xTax5EiBF85D-hYmmbDsGDJLYn2uPYBbbkK_YzGS_NTq7pwMAiYROe1KBS3AU36wHIRQ=\" rel=\"nofollow\" target=\"_blank\">jtarazi@aligos.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Inizio Evoke<br \/>Jake Robison<br \/>Vice President<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jbs5aWihUBjKk_3DtodMHVB4OUfn8KAOtupd-BTW2yldJYvC70RSZj2Y2kmjQrO9rpb0M2k79_uo9yX192-QJJXO6otYsmIU8ar-TZrl9DAMLRW6p8Utc9hilRv0xx19\" rel=\"nofollow\" target=\"_blank\">Jake.Robison@inzioevoke.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTg5OGRlNTAtMjNmNi00ODVlLWFhMDktOTExNjRkNDNkMjE1LTEyMTU0NjktMjAyNi0wMS0xMy1lbg==\/tiny\/Aligos-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (\u201cAligos\u201d, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company\u2019s global commercial capabilities and serve as a member of Aligos\u2019 Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. \u201cAs we continue to progress the Phase 2 B-SUPREME study of pevifoscorvir sodium, we have begun planning for the future and how best to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926765","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (\u201cAligos\u201d, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company\u2019s global commercial capabilities and serve as a member of Aligos\u2019 Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. \u201cAs we continue to progress the Phase 2 B-SUPREME study of pevifoscorvir sodium, we have begun planning for the future and how best to &hellip; Continue reading &quot;Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:58:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer\",\"datePublished\":\"2026-01-13T13:58:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/\"},\"wordCount\":724,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/\",\"name\":\"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=\",\"datePublished\":\"2026-01-13T13:58:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Market Newsdesk","og_description":"Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (\u201cAligos\u201d, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company\u2019s global commercial capabilities and serve as a member of Aligos\u2019 Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. \u201cAs we continue to progress the Phase 2 B-SUPREME study of pevifoscorvir sodium, we have begun planning for the future and how best to &hellip; Continue reading \"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-13T13:58:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer","datePublished":"2026-01-13T13:58:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/"},"wordCount":724,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/","name":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=","datePublished":"2026-01-13T13:58:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDI3MiM3MzU3MjMxIzIyMDM5MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-james-hassard-as-executive-vice-president-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926765"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926765\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}